Effect of doxycycline on postoperative scarring after trabeculectomy in an experimental rabbit model.
OBJECTIVE
To investigate effectiveness of doxycycline after trabeculectomy in rabbits by evaluating bleb appearance, intraocular pressure, and levels of matrix metalloproteinase-1, -2, -3, and -9 and tissue inhibitors of metalloproteinase (TIMP)-1 and -2 in the subconjunctival (sc) area.


METHODS
Twenty-nine New Zealand White rabbits were assigned into 1 of 6 groups as follows: topical doxycycline (0.1%), postoperative sc injection of doxycycline (100 mg/2 mL), and intraoperative mitomycin-C (MMC) (0.2 mg/mL) and their respective control groups.


RESULTS
There was significant difference between intraocular pressure in the case groups, but there was no significant difference in topical doxycycline and MMC groups during the follow up. In the topical doxycycline group, levels of TIMP-1 and perifericTIMP-1 were higher and levels of perifericMMP-2 and inflammation were lower than their controls. In the sc doxycycline group, peripheral inflammation was higher than in the corresponding control. Only peripheral inflammation was significantly different between case groups, with the highest level in sc and the lowest level in MMC groups. Further, topical doxycycline group showed no significant difference in bleb appearance or peripheral inflammation compared with MMC group. Conjunctival burn and corneal vascularization were detected only in the sc doxycycline group.


CONCLUSIONS
Topical doxycycline is more effective than sc doxycycline but is similar to MMC, and it can be an alternative to MMC in trabeculectomy in rabbits.
Sen
Emine
E
Ulucanlar Eye Education and Research Hospital , Ankara, Turkey. eminesentr@yahoo.com
Balikoglu-Yilmaz
Melike
M
Bozdag-Pehlivan
Sibel
S
Sungu
Nuran
N
Aksakal
Fatma Nur
FN
Altinok
Ayse
A
Tuna
Tulay
T
Unlu
Nursen
N
Ustun
Huseyin
H
Koklu
Gultekin
G
Öztürk
Faruk
F
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D001768:Blister / Q000473:pathology / Q000601:surgery; D002921:Cicatrix / Q000150:complications* / Q000473:pathology; D003228:Conjunctiva / Q000187:drug effects / Q000473:pathology / Q000601:surgery; D004318:Doxycycline / Q000494:pharmacology*; D005260:Female; D005901:Glaucoma / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D007249:Inflammation / Q000378:metabolism; D007429:Intraocular Pressure / Q000187:drug effects; D007430:Intraoperative Care; D045726:Metalloproteases / Q000494:pharmacology; D016685:Mitomycin / Q000494:pharmacology; D023421:Models, Animal; D011184:Postoperative Period; D011817:Rabbits; D019714:Tissue Inhibitor of Metalloproteinases / Q000494:pharmacology; D014130:Trabeculectomy; D014945:Wound Healing / Q000187:drug effects
D000900:Anti-Bacterial Agents; D000903:Antibiotics, Antineoplastic; D019714:Tissue Inhibitor of Metalloproteinases; D016685:Mitomycin; D045726:Metalloproteases; D004318:Doxycycline